Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Manasanch EE, et al. Among authors: feng l. Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1. Lancet Haematol. 2018. PMID: 30501870 Clinical Trial.
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Tabchi S, et al. Among authors: feng l. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):560-569. doi: 10.1016/j.clml.2019.05.001. Epub 2019 May 17. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31201134 Free PMC article. Review.
Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.
Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Manasanch EE, et al. Among authors: feng l. Haematologica. 2020 May;105(5):e242-e245. doi: 10.3324/haematol.2019.225375. Epub 2019 Aug 14. Haematologica. 2020. PMID: 31413094 Free PMC article. Clinical Trial. No abstract available.
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. Lee HC, et al. Among authors: feng l. Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. Blood Cancer J. 2019. PMID: 31575851 Free PMC article. Clinical Trial. No abstract available.
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.
Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Kunacheewa C, et al. Among authors: feng l. Clin Lymphoma Myeloma Leuk. 2020 May;20(5):e221-e238. doi: 10.1016/j.clml.2020.01.001. Epub 2020 Jan 15. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32037287 Free PMC article. Clinical Trial.
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.
Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Kunacheewa C, et al. Among authors: feng l. Br J Haematol. 2021 May;193(3):e23-e26. doi: 10.1111/bjh.17393. Epub 2021 Mar 21. Br J Haematol. 2021. PMID: 33748943 No abstract available.
12,022 results
You have reached the last available page of results. Please see the User Guide for more information.